247 related articles for article (PubMed ID: 23762839)
1. Hp-β-CD-voriconazole in situ gelling system for ocular drug delivery: in vitro, stability, and antifungal activities assessment.
Pawar P; Kashyap H; Malhotra S; Sindhu R
Biomed Res Int; 2013; 2013():341218. PubMed ID: 23762839
[TBL] [Abstract][Full Text] [Related]
2. Design and evaluation of HP-β-CD based voriconazole formulations for ocular drug delivery.
Pahuja P; Kashyap H; Pawar P
Curr Drug Deliv; 2014; 11(2):223-32. PubMed ID: 24365062
[TBL] [Abstract][Full Text] [Related]
3. Optimizing ophthalmic delivery of a poorly water soluble drug from an aqueous in situ gelling system.
Senjoti FG; Timmins P; Conway BR; Smith AM
Eur J Pharm Biopharm; 2020 Sep; 154():1-7. PubMed ID: 32599271
[TBL] [Abstract][Full Text] [Related]
4. Thermosensitive and pH induced in situ ophthalmic gelling system for ciprofloxacin hydrochloride: hydroxypropyl-beta-cyclodextrin complex.
Başaran B; Bozkir A
Acta Pol Pharm; 2012; 69(6):1137-47. PubMed ID: 23285675
[TBL] [Abstract][Full Text] [Related]
5. Mucoadhesive in situ gel formulation for vaginal delivery of clotrimazole: formulation, preparation, and in vitro/in vivo evaluation.
Rençber S; Karavana SY; Şenyiğit ZA; Eraç B; Limoncu MH; Baloğlu E
Pharm Dev Technol; 2017 Jun; 22(4):551-561. PubMed ID: 27055376
[TBL] [Abstract][Full Text] [Related]
6. Ophthalmic controlled release in situ gelling systems for ciprofloxacin based on polymeric carriers.
Al-Kassas RS; El-Khatib MM
Drug Deliv; 2009 Apr; 16(3):145-52. PubMed ID: 19514974
[TBL] [Abstract][Full Text] [Related]
7. Thermoresponsive fluconazole gels for topical delivery: rheological and mechanical properties, in vitro drug release and anti-fungal efficacy.
Gandra SC; Nguyen S; Nazzal S; Alayoubi A; Jung R; Nesamony J
Pharm Dev Technol; 2015 Jan; 20(1):41-9. PubMed ID: 24160864
[TBL] [Abstract][Full Text] [Related]
8. Preparation and evaluation of a Carbopol/HPMC-based in situ gelling ophthalmic system for puerarin.
Wu C; Qi H; Chen W; Huang C; Su C; Li W; Hou S
Yakugaku Zasshi; 2007 Jan; 127(1):183-91. PubMed ID: 17202799
[TBL] [Abstract][Full Text] [Related]
9. Preparation and stability of voriconazole eye drop solution.
Dupuis A; Tournier N; Le Moal G; Venisse N
Antimicrob Agents Chemother; 2009 Feb; 53(2):798-9. PubMed ID: 19001119
[TBL] [Abstract][Full Text] [Related]
10. In vitro efficacy of the combination of voriconazole and anidulafungin against voriconazole-resistant cyp51A mutants of Aspergillus fumigatus.
Krishnan-Natesan S; Wu W; Chandrasekar PH
Diagn Microbiol Infect Dis; 2012 Jun; 73(2):135-7. PubMed ID: 22608136
[TBL] [Abstract][Full Text] [Related]
11. Novel in situ gelling ophthalmic drug delivery system based on gellan gum and hydroxyethylcellulose: Innovative rheological characterization, in vitro and in vivo evidence of a sustained precorneal retention time.
Destruel PL; Zeng N; Seguin J; Douat S; Rosa F; Brignole-Baudouin F; Dufaÿ S; Dufaÿ-Wojcicki A; Maury M; Mignet N; Boudy V
Int J Pharm; 2020 Jan; 574():118734. PubMed ID: 31705970
[TBL] [Abstract][Full Text] [Related]
12. Sodium alginate in oil-poloxamer organogels for intravaginal drug delivery: Influence on structural parameters, drug release mechanisms, cytotoxicity and in vitro antifungal activity.
Querobino SM; de Faria NC; Vigato AA; da Silva BGM; Machado IP; Costa MS; Costa FN; de Araujo DR; Alberto-Silva C
Mater Sci Eng C Mater Biol Appl; 2019 Jun; 99():1350-1361. PubMed ID: 30889669
[TBL] [Abstract][Full Text] [Related]
13. Development and characterization of thermosensitive pluronic-based metronidazole in situ gelling formulations for vaginal application.
Ibrahim el-SA; Ismail S; Fetih G; Shaaban O; Hassanein K; Abdellah NH
Acta Pharm; 2012 Mar; 62(1):59-70. PubMed ID: 22472449
[TBL] [Abstract][Full Text] [Related]
14. Microemulsions as vehicles for topical administration of voriconazole: formulation and in vitro evaluation.
El-Hadidy GN; Ibrahim HK; Mohamed MI; El-Milligi MF
Drug Dev Ind Pharm; 2012 Jan; 38(1):64-72. PubMed ID: 21696340
[TBL] [Abstract][Full Text] [Related]
15. [Stability and in vitro activity of voriconazole eyedrops at a concentration of 3 microg/mL].
Isla Tejera B; Garzas Martín de Almagro C; Cárdenas Aranzana M; Pérez Rodrigo I; Aumente Rubio MD; Gordillo Sánchez R
Farm Hosp; 2005; 29(5):331-4. PubMed ID: 16351455
[TBL] [Abstract][Full Text] [Related]
16. Synergetic skin targeting effect of hydroxypropyl-β-cyclodextrin combined with microemulsion for ketoconazole.
Che J; Wu Z; Shao W; Guo P; Lin Y; Pan W; Zeng W; Zhang G; Wu C; Xu Y
Eur J Pharm Biopharm; 2015 Jun; 93():136-48. PubMed ID: 25845772
[TBL] [Abstract][Full Text] [Related]
17. Kolliphor® HS 15-cyclodextrin Complex for the Delivery of Voriconazole: Preparation, Characterization, and Antifungal Activity.
Li Y; Zhu C; Wu H; Pan H; Liu H
Curr Drug Metab; 2020; 21(5):379-389. PubMed ID: 32432999
[TBL] [Abstract][Full Text] [Related]
18. In vitro susceptibilities of Aspergillus species to voriconazole, itraconazole, and amphotericin B.
Abraham OC; Manavathu EK; Cutright JL; Chandrasekar PH
Diagn Microbiol Infect Dis; 1999 Jan; 33(1):7-11. PubMed ID: 9990469
[TBL] [Abstract][Full Text] [Related]
19. Potential Use of Cyclodextrin Complexes for Enhanced Stability, Anti-inflammatory Efficacy, and Ocular Bioavailability of Loteprednol Etabonate.
Soliman OAE; Mohamed EAM; El-Dahan MS; Khatera NAA
AAPS PharmSciTech; 2017 May; 18(4):1228-1241. PubMed ID: 27469220
[TBL] [Abstract][Full Text] [Related]
20. Formulation and evaluation of voriconazole ophthalmic solid lipid nanoparticles in situ gel.
Pandurangan DK; Bodagala P; Palanirajan VK; Govindaraj S
Int J Pharm Investig; 2016; 6(1):56-62. PubMed ID: 27014620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
